T-cell inhibitors: A bench-to-bedside review

Dermatitis

Volumn 23, Issue 5, 2012, Pages 195-202

  Das, Shinjita ^a   Ariizumi, Kiyoshi ^a   Cruz, Ponciano D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; ABATACEPT; B7 ANTIGEN; BELATACEPT; CD40 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ECALECTIN; GLYCOPROTEIN; HERPESVIRUS ENTRY MEDIATOR LIGAND; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; IPILIMUMAB; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MUCIN 3; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BTLA 4; PROTEIN DC HIL; PROTEIN TIM 3; PROTEOHEPARAN SULFATE; SYNDECAN 4; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CARCINOGENESIS; CELLULAR IMMUNITY; CLONAL ANERGY; DRUG MECHANISM; GRAFT REJECTION; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; LUPUS ERYTHEMATOSUS NEPHRITIS; MELANOMA; MELANOMA METASTASIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SKIN ALLERGY; SKIN LYMPHOMA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; ULCERATIVE COLITIS;

EID: 84871258545     PISSN: 17103568     EISSN: None     Source Type: Journal    
DOI: 10.1097/DER.0b013e31826e43ed     Document Type: Review

References (79)

1. Curtsinger JM, MescherMF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010;22:333-340.
2. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009;27:591-619.
3. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol 2002;20:29-53.
4. Murphy KM, Nelson CA, Sedy Jr. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 2006;6:671-681.
5. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-824.
6. Chung JS, Dougherty I, Cruz PD Jr, et al. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J Immunol 2007; 179:5778-5784.
7. Sabatos CA, Chakravarti S, Cha E, et al. Interaction of TIM-3 and TIM-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003;4:1102-1110.
8. Hastings WD, Anderson DE, Kassam N, et al. TIM-3 is expressed on activated CD4+ T cells and regulates TH1 and TH17 cytokines. Eur J Immunol 2009;39:2492-2501.
9. Anderson AC, Anderson DE, Bregoli L, et al. Promotion of tissue inflammation by the immune receptor TIM-3 expressed on innate immune cells. Science 2007;318:1141-1143.
10. Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamilyYCTLA-4. Nature 1987;328:267-270.
11. Harper K, Balzano C, Rouvier E, et al. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J Immunol 1991;147:1037-1044.
12. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
13. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
14. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-465.
15. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541-547.
16. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-3895.
17. Nishimura H, Minato N, Nakano T, et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol 1998;10:1563-1572.
18. Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-151.
19. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034.
20. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD- 1 and inhibits T cell activation. Nat Immunol 2001;2:261-268.
21. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003;4:670-679.
22. Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005;6:90-98.
23. Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A 2005; 102:1116-1121.
24. Cai G, Freeman G. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 2009; 229:244-258.
25. Krieg C, Boyman O, Fu YX, et al. B and T lymphocyte attenuator regulates CD8+ T cellYintrinsic homeostasis and memory cell generation. Nat Immunol 2007;8:162-171.
26. Monney L, Sabatos CA, Gaglia JL, et al. TH1-specific cell surface protein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415:536-541.
27. Sanchez-Fueyo A, Tian J, Picarella D, et al. TIM-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003;4:1093-1101.
28. Zhu C, Anderson AC, Schubart A, et al. The TIM-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245-1252.
29. Shikano S, Bonkobara M, Zukas PK, et al. Molecular cloning of a dendritic cellYassociated transmembrane protein, DC-HIL, that promotes RGDdependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J Biol Chem 2001;276:8125-8134.
30. Chung JS, Sato K, Dougherty II, et al. DC-HIL is a negative regulator of T lymphocyte activation. Blood 2007;109:4320-4327.
31. Chung JS, Bonkobara M, Tomihari M, et al. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses. Eur J Immunol 2009;39:965-974.
32. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over FOXP3+ regulatory T cell function. Science 2008;322:271-275.
33. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory Tcells and immune tolerance. Cell 2008;133:775-787.
34. Onishi Y, Fehervari Z, Yamaguchi T, et al. FOXP3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008;105: 10113-10118.
35. Oya Y,Watanabe N, Owada T, et al. Development of autoimmune hepatitislike disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum2008;58:2498-2510.
36. Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506-511.
37. Jury EC, Flores-Borja F, Kalsi HS, et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol 2010;40:569-578.
38. Barreto M, Ferreira RC, Lourenco L, et al. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunol 2009;10:5.
39. Kobayashi M, Kawano S, Hatachi S, et al. Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjogren's syndrome. J Rheumatol 2005;32:2156-2163.
40. Prokunina L, Castillejo-Lopez C, Oberg F, et al. A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002;32:666-669.
41. Nielsen C, Hansen D, Husby S, et al. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 2003;62:492-497.
42. Kong EK, Prokunina-Olsson L, Wong WH, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005;52:1058-1062.
43. Kroner A, Mehling M, Hemmer B, et al. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol 2005;58:50-57.
44. NishimuraH,Okazaki T, Tanaka Y, et al. Autoimmune dilated cardiomyopathy in PD-1 receptorYdeficient mice. Science 2001;291:319-322.
45. Wang Y, Meng J, Wang X, et al. Expression of human TIM-1 and TIM-3 on lymphocytes from systemic lupus erythematosus patients. Scand J Immunol 2008;67:63-70.
46. Yang L, Anderson DE, Kuchroo J, et al. Lack of TIM-3 immunoregulation in multiple sclerosis. J Immunol 2008;180:4409-4414.
47. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63-69.
48. Truong W, Hancock WW, Plester JC, et al. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol 2009;86:41-51.
49. Seki M, Sakata KM, Oomizu S, et al. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum 2007;56:3968-3976.
50. Seki M, Oomizu S, Sakata KM, et al. Galectin-9 suppresses the generation of TH17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008;127:78-88.
51. Sugiyama H, Gyulai R, Toichi E, et al. Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 2005; 174:164-173.
52. Niwa H, Satoh T, Matsushima Y, et al. Stable form of galectin-9, a TIM-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for TH1- and/or TH17-mediated skin inflammation. Clin Immunol 2009;132:184-194.
53. Viglietta V, Bourcier K, Buckle GJ, et al. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology 2008;71:917-924.
54. Tang A, Judge TA, Nickoloff BJ, et al. Suppression of murine allergic contact dermatitis by CTLA4Ig. Tolerance induction of TH2 responses requires additional blockade of CD40-ligand. J Immunol 1996;157:117-125.
55. Schwarz A, Beissert S, Grosse-Heitmeyer K, et al. Evidence for functional relevance of CTLA-4 in ultraviolet-radiation-induced tolerance. J Immunol 2000;165:1824-1831.
56. Akiyoshi H, Chung JS, Tomihari M, et al. Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cellYassociated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cellYdriven disease. J Immunol 2010;184:3554-3561.
57. Tao R, Wang L, Han R, et al. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 2005;175:5774-5782.
58. Ozkaynak E, Wang L, Goodearl A, et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002;169:6546-6553.
59. Yang J, Popoola J, Khandwala S, et al. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 2008;117:660-669.
60. Dudler J, Li J, Pagnotta M, et al. Gene transfer of programmed death ligand- 1.Ig prolongs cardiac allograft survival. Transplantation 2006;82: 1733-1737.
61. Oikawa T, Kamimura Y, Akiba H, et al. Preferential involvement of TIM-3 in the regulation of hepatic CD8+ Tcells in murine acute graft-versus-host disease. J Immunol 2006;177:4281-4287.
62. Wang F, He W, Zhou H, et al. The TIM-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft. Cell Immunol 2007;250:68-74.
63. Wang F, He W, Yuan J, et al. Activation of TIM-3-galectin-9 pathway improves survival of fully allogeneic skin grafts. Transpl Immunol 2008;19:12-19.
64. He W, Fang Z, Wang F, et al. Galectin-9 significantly prolongs the survival of fully mismatched cardiac allografts in mice. Transplantation 2009;88:782-790.
65. Naka EL, Ponciano VC, Cenedeze MA, et al. Detection of the TIM-3 ligand, galectin-9, inside the allograft during a rejection episode. Int Immunopharmacol 2009;9:658-662.
66. Via CS, Rus V, Nguyen P, et al. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol 1996;157:4258-4267.
67. Shiraishi T, Yasunami Y, Takehara M, et al. Prevention of acute lung allograft rejection in rat by CTLA4Ig. Am J Transplant 2002;2:223-228.
68. Tikkanen JM, Lemstrom KB, Koskinen PK. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type 1-dominated immune response. Am J Respir Crit Care Med 2002;165:724-729.
69. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-781.
70. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
71. Szczepanski MJ, Szajnik M, Czystowska M, et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009;15:3325-3332.
72. Berger CL, Tigelaar R, Cohen J, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005;105:1640-1647.
73. Chung JS, Shiue LH, Duvic M, et al. Sezary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface. Blood 2011;117:3382-3390.
74. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
75. Tomihari M, Chung JS, Akiyoshi H, et al. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res 2010;70:5778-5787.
76. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002;99:12293-12297.
77. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
78. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiYprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
79. Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating Tcells and reduces regulatory Tand myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010; 107:4275-4280.